Gilead Sciences Stock Analysis, Valuation (NASDAQ:GILD)

Add to My Stocks
$83.61 $0.34 (0.41%) GILD stock closing price Sep 25, 2017 (Closing)
Watch Robo Advisor Video of GILD Stock Analysis
Gilead Sciences
Updated on : Sep 25, 2017
previous close
GILD 83.6 (0%)
S&P 500 2496.7 (0%)
Closing Price On: Sep 25, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Biomed-Genetics
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2017-Q2
$billion
%
YOY GROWTH
Compared to the industry
Operating Profit
Operating Margin:
57.8%
Sector Average:
-2.3%
5 Quarter Net Profit
Net Margins
2017-Q2
%
LTM Margin
Compared to the industry
Debt/Equity Ratio
Debt:
26.74B
Debt/Equity Ratio:
 1.16
Compared to the industry
Cash Flow
Operating cash flow:
$3.53B
Net Income:
$3.07B
Dividend Yield
GILD dividend yield:
2.37%
PROS      CONS
Operating Margins
Net Margins
ROIC
ROE
FCF Margin
PE Valuation
Recent Growth
High Debt Burden
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
GILD PS :
3.8
Industry PS :
5.4
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Invested Capital:
37.7%
Return on Equity:
63.1%
Free Cash Flow Margin:
47.7%
Double Tap To Exit Full Screen
0:00
/

Gilead Sciences Stock Analysis

7119 10 2

View Gilead Sciences stock analysis video. This is our analyst opinion covering the buy and sell arguments for GILD stock.

Gilead Sciences, Inc. Stock Rating 4.3/5

Our Gilead Sciences stock opinion is based on fundamentals of the company. This Gilead Sciences stock analysis is based on latest 2017 Q2 earnings. The stock price analysis takes into account the company's valuation metrics.

Should you buy GILD stock?

  • The TTM operating margin was good at 57.8% for Gilead Sciences.
  • LTM Net margins were good at 42.9% for Gilead Sciences.
  • The price to earnings multiple of 8.3 is attractive when compared with the industry average PE ratio of 22.8.
  • Gilead Sciences has an attractive ROIC (Return on Invested Capital) of 37.7%
  • The LTM ROE of 63.1% for Gilead Sciences is attractive.
  • Gilead Sciences has a healthy FCF (Free Cash Flow) margin of 47.7%.

Should you sell GILD stock?

  • Gilead Sciences sales declined by -8.2% year on year in 2017 Q2.
  • Gilead Sciences is debt laden and has a high debt/equity ratio of  1.16.

Comments on this video and Gilead Sciences stock